You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma

  • Authors: Arnaud Bourdin, MD, PhD; Eugene R. Bleecker, MD; Ian Pavord, MD, PhD
  • CPD Released: 7/26/2019; Reviewed and Renewed: 2/4/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 2/4/2022
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US primary care physicians, pulmonologists, and allergists & clinical immunologists and other health professionals involved in the care of patients with asthma.

The goal of this activity is to improve physician education regarding the current treatment recommendations for severe asthma, including the need to reduce the use of oral corticosteroids (OCS) and the role and best use of biologic therapies to optimize clinical outcomes and patient expectation of treatment.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Adverse effects of OCS overuse in severe asthma
    • Emerging clinical data evaluating the ability of different biologic therapies to reduce the need for OCS use in severe asthma
  • Demonstrate greater confidence in their ability to
    • Prescribe appropriate biologic therapy for severe asthma while minimizing OCS use


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Arnaud Bourdin, MD, PhD

    Head, Department of Respiratory Diseases
    University of Montpellier
    Montpellier, France

    Disclosures

    Disclosure: Arnaud Bourdin, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Actelion Pharmaceuticals, Ltd.; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici SpA; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Sanofi-Regeneron
    Served as a speaker or a member of a speakers bureau for: Actelion Pharmaceuticals, Ltd.; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici SpA; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Sanofi-Regeneron
    Received grants for clinical research from: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline

  • Eugene R. Bleecker, MD

    Professor and Co-Chief
    Genetics, Genomics and Precision Medicine
    Department of Medicine
    Co-Director, Division of Pharmacogenomics
    Center for Applied Genetics and Genomics Medicine
    University of Arizona Health Sciences
    Tucson, Arizona, United States

    Disclosures

    Disclosure: Eugene R. Bleecker, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ALK-Abello; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; MedImmune, Inc.; Novartis Pharmaceuticals Corporation; Regeneron; Sanofi-Genzyme; Teva
    Received grants for clinical research from: AstraZeneca; Genentech-Roche; GlaxoSmithKline; MedImmune, Inc.; Novartis Pharmaceuticals Corporation; Sanofi-Genzyme; Teva

  • Ian D. Pavord, MBBS, DM, FRCP, FERS FmedSci

    Professor
    Nuffield Department of Medicine and Oxford Respiratory BRC
    University of Oxford
    Oxford, Oxon, United Kingdom

    Disclosures

    Disclosure: Ian D. Pavord, MBBS, DM, FRCP, FERS FmedSci, has disclosed no relevant financial relationships.

Editor

  • Walid Amara, MD

    Scientific Director, WebMD Global, LLC

    Disclosures

    Disclosure: Walid Amara, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: BIOTRONIK; SERVIER
    Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol-Myers Squibb Company; Livanova; MEDA; Medtronic, Inc.; MSD; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Physiomed; St. Jude, SERVIER

Content Reviewer

  • Nafeez Zawahir, MD

    CME Clinical Director

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma

Authors: Arnaud Bourdin, MD, PhD; Eugene R. Bleecker, MD; Ian Pavord, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 7/26/2019; Reviewed and Renewed: 2/4/2021

Valid for credit through: 2/4/2022

processing....

Educational Impact Challenge

The goal of this activity is to improve physician education regarding the current treatment recommendations for severe asthma, including the need to reduce the use of oral corticosteroids (OCS) and the role and best use of biologic therapies to optimize clinical outcomes and patient expectation of treatment.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print